{"id":"polio-sabin-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This immune response helps the body develop antibodies to fight the poliovirus, providing protection against polio infection. The weakened virus is unable to cause disease but still triggers an immune response, which is essential for long-term immunity.","oneSentence":"The Polio Sabin vaccine works by introducing a weakened form of the poliovirus to stimulate an immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:24.186Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis"}]},"trialDetails":[{"nctId":"NCT03848065","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-04-02","conditions":"Pneumococcal Infections","enrollment":133},{"nctId":"NCT04232943","phase":"PHASE1","title":"Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2020-01-22","conditions":"Polio","enrollment":87},{"nctId":"NCT02521974","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2015-10","conditions":"Adverse Event Following Immunisation","enrollment":164},{"nctId":"NCT02582255","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2015-11","conditions":"Poliomyelitis","enrollment":100},{"nctId":"NCT00678301","phase":"PHASE3","title":"Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-18","conditions":"Infections, Streptococcal","enrollment":365},{"nctId":"NCT01345240","phase":"PHASE3","title":"Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Malaria, Malaria Vaccines","enrollment":705},{"nctId":"NCT01098474","phase":"PHASE2","title":"Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-07","conditions":"Tuberculosis","enrollment":301},{"nctId":"NCT01262872","phase":"PHASE2","title":"Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-09","conditions":"Infections, Streptococcal","enrollment":1320},{"nctId":"NCT00547248","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-22","conditions":"Infections, Streptococcal","enrollment":756},{"nctId":"NCT00344318","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-07","conditions":"Infections, Streptococcal","enrollment":806},{"nctId":"NCT00436007","phase":"PHASE2","title":"Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-30","conditions":"Malaria","enrollment":511}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":145,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Polio Sabin™ vaccine","genericName":"Polio Sabin™ vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"The Polio Sabin vaccine works by introducing a weakened form of the poliovirus to stimulate an immune response. Used for Prevention of poliomyelitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}